Biomarker ID | 1995 |
PMID | 22589488 |
Year | 2012 |
Biomarker | Methylation status of PHLDA 3 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethlated in Recurrent prostate cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Clinical recurrence vs. biochemical recurrence |
Type of Biomarker | Prognostic |
Cohort | clinical recurrence (n = 80) versus biochemical recurrence (n = 43) |
Senstivity | Training: 61.0 (47.4–73.4); Validation:65.6 (40.7–84.6) |
Specificity | Training:59.0 (42.1–74.4); validation: 65.0 (40.7–84.6) |
AUC | Training: 0.606; validation:0.73 |
Accuracy | NA |
Level Of Significance | <0.0772 |
Method Used | Pyrosequencing |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | PHLDA 3 |